← Leaderboards
Jeremiah Andrew Alt
Glycomira, Llc
$1,302,634
Attributed
$2,704,473
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $841.6K · FY2016–20$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,704,473 · 2
By mechanism
R44$2,406,859 · 1
R43$297,614 · 1
Top collaborators
- Abigail Pulsipher4 shared
- Glenn D Prestwich1 shared
Most similar at Glycomira, Llc
Same institution · by research overlap
- Abigail Pulsipher$2,897,859
- Justin Rodney Savage$2,775,433
Others in their field
Top investigators on “Hyperplasia”
- Devendra K. Agrawal · Creighton University$23,515,446
- Scott W Wong · Oregon Health And Science University$21,099,510
- Frank W Logerfo · Beth Israel Deaconess Medical Center$21,014,586
- Kenneth M Kaye · Brigham And Women'S Hospital$17,592,088
- Shou-Jiang Gao · University Of Texas Hlth Science Center$16,034,253
- Jae U Jung · Cleveland Clinic Lerner Com-Cwru$15,743,600
Research focus
HyperplasiaInflammatoryEffective TherapyHealth ExpendituresInflammationInflammation MediatorsChemotaxisDoseEosinophilGlycosaminoglycansImmuneInfiltrationChronicChronic RhinosinusitisAffectAspergillus FumigatusBaseAmericanCellsChemokineAnimalsEtiologyComplexIrrigation
Grant awards (4)
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$783,698
R44 · FY2020 · AI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$841,614
R44 · FY2019 · AI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$781,547
R44 · FY2018 · AI
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$297,614
R43 · FY2016 · AI